Die Rolle der molekularen Bildgebung (PET-CT) in der Diagnostik und Therapie des Prostatakarzinoms-Reference-Cited by-同舟云学术

Die Rolle der molekularen Bildgebung (PET-CT) in der Diagnostik und Therapie des Prostatakarzinoms

Published:2018-10-22 Issue:1-2 Volume:169 Page:12-14
ISSN:0043-5341
Container-title:Wiener Medizinische Wochenschrift
language:de
Short-container-title:Wien Med Wochenschr

Author:

Mirzaei Siroos,Knoll Peter,Zandieh Shahin

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/article/10.1007/s10354-018-0668-5/fulltext.html

Reference10 articles.

1. Statistik Austria. Prostata. 2018. http://www.statistik.at/web_de/statistiken/menschen_und_gesellschaft/gesundheit/krebserkrankungen/prostata/index.html . Zugegriffen: 20. Juli 2018.

2. Eiber M, Röthke MC. Diagnose und Ausbereitungsdiagnostik des Prostatakarzinoms. Forum Fam Plan West Hemisph. 2016;31:115–20.

3. Kranzbühler B, Nagel H, Becker AS, et al. Clinical performance of 68 Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2018;45:20–30.

4. Thomas L, Balmus C, Ahmadzadehfar H, et al. Assessment of bone metastases in patients with prostate cancer-a comparison between (99m)Tc-bone-scintigraphy and [(68)Ga]Ga-PSMA PET/CT. Pharmaceuticals (Basel). 2017;10:68–78.

5. Abikhzer G, Srour S, Fried G, et al. Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer. Nucl Med Commun. 2016;37:1160–8.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Theranostics of Metastatic Prostate Cancer Applying 64Cu/18F/68Ga PSMA PET-CT and 177Lu Radiopharmaceuticals;Current Radiopharmaceuticals;2021-11-10

2. Peptide and pseudo-peptide;The Quarterly Journal of Nuclear Medicine and Molecular Imaging;2020-12

3. A 64 Cu-porphyrin-based dual-modal molecular probe with integrin αv β3 targeting function for tumour imaging;Journal of Labelled Compounds and Radiopharmaceuticals;2020-03-06